Search

Your search keyword '"Laurent, L."' showing total 502 results

Search Constraints

Start Over You searched for: Author "Laurent, L." Remove constraint Author: "Laurent, L." Topic anti-bacterial agents Remove constraint Topic: anti-bacterial agents
502 results on '"Laurent, L."'

Search Results

1. Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases.

2. UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract.

3. The OprF porin as a potential target for the restoration of carbapenem susceptibility in Pseudomonas aeruginosa expressing acquired carbapenemases.

4. Oxacillinase-484-Producing Enterobacterales, France, 2018-2023.

5. Eyelid and periorbital necrotizing fasciitis, a severe preseptal infection, a systemic review of the literature and anatomical illustrations.

6. Prenatal and infant exposure to antibiotics and subsequent risk of neuropsychiatric disorders in children: A nationwide birth cohort study in South Korea.

7. Proof of concept study on early forecasting of antimicrobial resistance in hospitalized patients using machine learning and simple bacterial ecology data.

8. Case report: Personalized triple phage-antibiotic combination therapy to rescue necrotizing fasciitis caused by Panton-Valentine leukocidin-producing MRSA in a 12-year-old boy.

9. Impact of Water Saturation on the Fate and Mobility of Antibiotics in Reactive Porous Geomedia.

10. Adjunctive intravesical EDTA-tromethamine treatment of a biofilm-associated recurrent Escherichia coli cystitis in a dog.

11. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.

12. Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa.

13. MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections.

14. Characterisation of a novel AmpC beta-lactamase, DHA-33, resistant to inhibition by cloxacillin.

15. Multifunctional host-defense peptides isolated from skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae).

16. Mutation Rate of AmpC β-Lactamase-Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution.

17. Amide bioisosteric replacement in the design and synthesis of quorum sensing modulators.

18. Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol.

19. IMI-Type Carbapenemase-Producing Enterobacter cloacae Complex, France and Overseas Regions, 2012-2022.

20. Spread of carbapenemase-producing Morganella spp from 2013 to 2021: a comparative genomic study.

21. Dissemination of extensively drug-resistant NDM-producing Providencia stuartii in Europe linked to patients transferred from Ukraine, March 2022 to March 2023.

22. Design of Triazolium-Grafted Peptidomimetic Macrocycles with Facial Amphipathicity to Target Pathogenic Bacteria.

23. Providing insight into the mechanism of action of cationic lipidated oligomers using metabolomics.

24. Evaluation and activity of new porphyrin-peptide cage-type conjugates for the photoinactivation of Mycobacterium abscessus .

25. Comparison of the French novel disc diffusion-based algorithm and the current EUCAST guidelines for the screening of carbapenemase-producing Enterobacterales.

26. Role of amino acid 159 in carbapenem and temocillin hydrolysis of OXA-933, a novel OXA-48 variant.

27. Lack of Synergistic Nephrotoxicity in a Mouse Model of Vancomycin-Induced AKI with Piperacillin-Tazobactam Coadministration.

28. Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.

29. In Utero Exposure to Antibiotics and Risk of Serious Infections in the First Year of Life.

30. Accraspiroketides A-B, Phenylnaphthacenoid-Derived Polyketides with Unprecedented [6 + 6+6 + 6] + [5 + 5] Spiro-Architecture.

31. Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis.

32. Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales.

33. Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group.

34. Implementation of an antibiotic resistance surveillance tool in Madagascar, the TSARA project: a prospective, observational, multicentre, hospital-based study protocol.

36. Structural basis of metallo-β-lactamase resistance to taniborbactam.

37. High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against nontuberculous mycobacteria in vitro and in vivo.

38. A highly conserved ligand-binding site for AccA transporters of antibiotic and quorum-sensing regulator in Agrobacterium leads to a different specificity.

39. Towards optimization of ceftazidime dosing in obese ICU patients: the end of the 'one-size-fits-all' approach?

40. Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii.

41. Rapid detection of imipenem/relebactam susceptibility/resistance in Enterobacterales.

42. Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales.

43. Impact of veterinary antibiotics on plasmid-encoded antibiotic resistance transfer.

44. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.

45. Discovering NDM-1 inhibitors using molecular substructure embeddings representations.

46. Prevalence and impacts of self-medication in a disadvantaged setting: the importance of multi-dimensional health interventions.

47. A Selective Culture Medium for Screening Cefiderocol Resistance in Enterobacterales , Pseudomonas aeruginosa, and Acinetobacter baumannii.

48. Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria.

50. Scope and Limitations of Exploiting the Ability of the Chemosensitizer NV716 to Enhance the Activity of Tetracycline Derivatives against Pseudomonas aeruginosa .

Catalog

Books, media, physical & digital resources